TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05805202

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling and urine analysis
Description: A blood sample of 10- 20 ml from pediatric patients, 30-50 ml from adult patients will be collected for each patient and healthy voluntarees
Study: NCT05720702

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: homocysteine (Hcy) lowering supplements
Description: NAFLD participants will take homocysteine (Hcy) lowering supplements daily for 12 weeks.
Study: NCT05551936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: 90 mg/m\^2 IV Days 1-2, Cycles 1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 IV Day 1 Cycles 1-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: RP2D (400, 600, or 800 mg) orally twice daily Cycles 1-6
Study: NCT06687720

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MetBroma
Description: Mode of Usage: Take one slow-release capsule twice a day, after meal Dosage Form: Capsule Unit Dose Route of administration: Oral frequency: Twice a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: MetBroma
Description: Mode of Usage: Take one slow-release capsule twice a day, after meal Dosage Form: Capsule Unit Dose Route of administration: Oral frequency: Twice a day
Study: NCT06687863

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Includes aerobic exercise, strength training, streching
Study: NCT06689332

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment
Description: Comprehensive geriatric assessment (CGA) is performed by a geriatrician and a geriatric nurse. CGA in this study includes: Assessment of coexisting diseases and treatments. Review of medications and adjustments as needed. Assessment of symptoms and health related issues including screening for depression, dementia, delirium, nutritional problems, falls, polypharmacy and fatigue. Objective examination including blood tests and electrocardiogram. Assessment of activities of daily living and instrumental activities of daily living through standardized questionnaires. Assessment of domestic conditions, including need for assistance from community-based health care services. Assessment of physical function through history and physical tests. Based on the CGA findings, the geriatrician will initiate relevant interventions (including investigations or treatments) and follow-up as required.
Study: NCT06627595

Intervention type: DRUG
Intervention: Immunotherapy
Description: Patients will be treated in accordance with the guidelines for melanoma treatment.

Intervention type: DRUG
Intervention: Immunotherapy
Description: Patients will be treated in accordance with the guidelines for melanoma treatment.
Study: NCT06693973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AcNK-Sup003 cell injection solution
Description: The AcNK technology has successfully achieved the direct, covalent, and directional conjugation of intact antibodies which includes the Fc domain to the surface of NK cells via a one-step enzymatic reaction. This novel approach yields a non-genetically modified NK cell that is conjugated with dual-targeting antibodies, referred to as AcNK. Specifically, AcNK-Sup003 cells are cryopreserved NK cells that have been conjugated with bispecific antibodies target both CD20 and CD19.
Study: NCT06686342

Intervention type: OTHER
Intervention: No intervention
Description: The patients with R/M HNSCC would receive drug treatment according to the clinical guideline or doctor's experience, at the same time, tumor biopsy samples would be collected to establish PDO for drug sensitive test. But no intervention would be used based on the PDO drug sensitive test.

Intervention type: OTHER
Intervention: No Intervention: Observational Cohort
Description: The patients with R/M HNSCC would receive drug treatment according to the clinical guideline or doctor's experience, at the same time, tumor biopsy samples would be collected to establish PDO for drug sensitive test. But no intervention would be used based on the PDO drug sensitive test.
Study: NCT06686901

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone-delivered Therapeutic Evaluative Conditioning for Suicide (TEC-S)
Description: Therapeutic Evaluative Conditioning for Suicide (active TEC-S) is a behavioral treatment where participants are given optional access to a computerized task/game where they repeatedly pair suicidal behavior stimuli (pictures, words) with other negative stimuli and self-related stimuli with positive stimuli.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Smartphone-delivered inactive Therapeutic Evaluative Conditioning
Description: Therapeutic Evaluative Conditioning (inactive TEC-S) is a behavioral treatment where participants are given optional access to a computerized task/game where they repeatedly pair positive and negative stimuli (pictures, words) with each other.
Study: NCT06690372

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality exercise
Description: Over the 12-weeks, participants will be instructed to exercise with the VR-Move 3x/week for 30 minutes for 12-weeks total, with modules presented in a prescribed weekly sequence to provide novel and re-enforcement of modules, while ensuring all modules are performed. Further, participants will be provided the opportunity of a 30 minute free-play of module of choice once a module has been introduced.
Study: NCT06690528

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection of both the primary tumor and liver metastases
Description: Surgical resection of both the primary tumor and liver metastases. The surgical approach, extent of resection, and perioperative management will follow the standard protocols at each participating center. Venous vascular resections might be performed to reach radicality. Either standard or parenchyma sparing liver resections might be performed for resection of the liver metastases. Alternatively, needle ablation/microwave on the liver lesions is possible for lesions \<20 mm if technically feasible. Post-operative chemotherapy and/or radiotherapy could be administered as per multi-disciplinary decision based on case-by-case evaluation.
Study: NCT05902754

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Generally Recognized as Safe - Sulforaphane
Description: Participants will be asked to maintain the same food ingestion habits as before the study and take 2 tablets of Sulforaphane a day with a meal for 28 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be asked to maintain the same food ingestion habits as before the study and take 2 tablets of placebo a day with a meal for 28 days.
Study: NCT06504966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAB-22
Description: Single subcutaneous dose of 60 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAB-22
Description: Single subcutaneous dose of 60 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prolia®
Description: Single subcutaneous dose of 60 mg
Study: NCT05365880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liquid Lidocaine
Description: The investigational treatment is 2 mL of aqueous 2% lidocaine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The active placebo comparator will be provided to participant.
Study: NCT04835597

Intervention type: BEHAVIORAL
Intervention: Behavioral Assessment
Description: Complete movement assessment

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: SAE data is collected
Study: NCT06056544

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Client Centered Care Coordination
Description: During the initial C4 sessions, participants will be offered PrEP. For participants who initiate PrEP, C4 staff will provide an individualized PrEP initiation plan. During subsequent C4 sessions, C4 staff will review the prevention plan and goals with participants and use autonomy supportive counseling to address the barriers that are identified by participants that impact their motivation to use PrEP and adhere to PrEP through referrals to support services (e.g, PrEP access programs, addiction medicine services, housing, and job resources). In addition, the C4 staff will ensure any medical issues related to PrEP adherence are addressed by the site medical providers.
Study: NCT04674306

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: α-lactalbumin vaccine
Description: α-lactalbumin vaccine will be administered subcutaneously in rotating sites (vaccine will not be administered in the arms of any participant, due to likelihood of prior bilateral mastectomy).~DL1: 10 mcg~DL Original 2: 100 mcg~DL2: 100 mcg~DL3: 500 mcg~D1b: 50 mcg~D1e: 10 mcg~D1f: 20 mcg~D1g: 20 mcg (D1g will only be utilized if D1c is deemed too toxic)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: α-lactalbumin vaccine
Description: α-lactalbumin vaccine will be administered subcutaneously in rotating sites (vaccine will not be administered in the arms of any participant, due to likelihood of prior bilateral mastectomy).~DL1: 10 mcg~DL Original 2: 100 mcg~DL2: 100 mcg~DL3: 500 mcg~D1b: 50 mcg~D1e: 10 mcg~D1f: 20 mcg~D1g: 20 mcg (D1g will only be utilized if D1c is deemed too toxic)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: α-lactalbumin vaccine
Description: α-lactalbumin vaccine will be administered subcutaneously in rotating sites (vaccine will not be administered in the arms of any participant, due to likelihood of prior bilateral mastectomy).~DL1: 10 mcg~DL Original 2: 100 mcg~DL2: 100 mcg~DL3: 500 mcg~D1b: 50 mcg~D1e: 10 mcg~D1f: 20 mcg~D1g: 20 mcg (D1g will only be utilized if D1c is deemed too toxic)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zymosan
Description: Adjuvant used in vaccine preparation~DL1: 10 mcg~DL Original 2: 100 mcg~DL2: 10 mcg~DL3: 10 mcg~D1b: 10 mcg~D1e: 20 mcg~D1f: 20 mcg~D1g: 1o mcg (D1g will only be utilized if D1c is deemed too toxic)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zymosan
Description: Adjuvant used in vaccine preparation~DL1: 10 mcg~DL Original 2: 100 mcg~DL2: 10 mcg~DL3: 10 mcg~D1b: 10 mcg~D1e: 20 mcg~D1f: 20 mcg~D1g: 1o mcg (D1g will only be utilized if D1c is deemed too toxic)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zymosan
Description: Adjuvant used in vaccine preparation~DL1: 10 mcg~DL Original 2: 100 mcg~DL2: 10 mcg~DL3: 10 mcg~D1b: 10 mcg~D1e: 20 mcg~D1f: 20 mcg~D1g: 1o mcg (D1g will only be utilized if D1c is deemed too toxic)
Study: NCT06439771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YL202 should be intravenously infused
Description: For each patient, YL202 should be intravenously infused over 60±10 min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YL202 should be intravenously infused
Description: For each patient, YL202 should be intravenously infused over 60±10 min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YL202 should be intravenously infused
Description: For each patient, YL202 should be intravenously infused over 60±10 min.
Study: NCT05894564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: Fluvoxamine is a round golden 50 mg tablet that is scored on both sides - one side has APO and the other side has F50 with a partial bisect. All packaging will be labeled to indicate that the product is for investigational use, administered at a dose of 50 mg, twice daily for 10 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
Study: NCT06369662

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow cytometric immunophenotyping
Description: CD155 expression by flow cytometric immunophenotyping

Intervention type: DIAGNOSTIC_TEST
Intervention: Complete blood count
Description: Complete blood count with peripheral blood smear examination

Intervention type: DIAGNOSTIC_TEST
Intervention: Bone marrow aspiration
Description: Bone marrow aspiration at both diagnosis and follow up of patients

Intervention type: DIAGNOSTIC_TEST
Intervention: Cytogenetic testing
Description: Karyotyping or AML fluorescence in situ hybridization (FISH) panel for diagnosis and risk stratification of AML patients

Intervention type: DIAGNOSTIC_TEST
Intervention: FLT3-ITD using High resolution melting curve (HRM) analysis
Description: Detection of FLT3-ITD mutation in AML patinets
Study: NCT06329622

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: low-protein diet + Ketosteril
Description: low-protein diet (0.6-0.8g protein/kg body weight/day) and Ketosteril 0.12 g/kg body weight/day will be prescribed with the target energy intake of 25-30kcal/kg body weight/day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: low-protein diet
Description: low-protein diet (0.6-0.8g protein/kg body weight/day) with the target energy intake of 25-30kcal/kg body weight/day.
Study: NCT06086873

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant Type
Description: Patients enrolled in the study will be allocated to one of three implant groups:~* Group 1: NGA Implant (NobelActive TiUltraNP, Nobel Biocare AG, Switzerland)~* Group 2: BLX implant (BLX) modSLA Surface (BLX, SLActive, Roxolid, Institut Straumann AG, Switzerland)~* Group 3: TLX implant (TLX) modSLA Surface (TLX, SLActive, Roxolid, Institut Straumann AG, Switzerland).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant Type
Description: Patients enrolled in the study will be allocated to one of three implant groups:~* Group 1: NGA Implant (NobelActive TiUltraNP, Nobel Biocare AG, Switzerland)~* Group 2: BLX implant (BLX) modSLA Surface (BLX, SLActive, Roxolid, Institut Straumann AG, Switzerland)~* Group 3: TLX implant (TLX) modSLA Surface (TLX, SLActive, Roxolid, Institut Straumann AG, Switzerland).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant Type
Description: Patients enrolled in the study will be allocated to one of three implant groups:~* Group 1: NGA Implant (NobelActive TiUltraNP, Nobel Biocare AG, Switzerland)~* Group 2: BLX implant (BLX) modSLA Surface (BLX, SLActive, Roxolid, Institut Straumann AG, Switzerland)~* Group 3: TLX implant (TLX) modSLA Surface (TLX, SLActive, Roxolid, Institut Straumann AG, Switzerland).
Study: NCT06089746

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NIPT
Description: Coordinated suite of DME and training to support continuous maintenance of flexion posture during the 6 week trial.
Study: NCT06134999

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive Neuromodulation
Description: The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 10 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7.~Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Non-invasive Neuromodulation
Description: The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
Study: NCT05725655

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thermotherapy
Description: Hot baths directly after an exercise session
Study: NCT06380907

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZL-1102 1% w/w gel BID for 16 weeks
Description: ZL-1102~1% w/w gel BID for 16 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZL-1102 3% w/w gel BID for 16 weeks
Description: ZL-1102 3% w/w gel BID for 16 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZL-1102 3% w/w gel QD for 16 weeks
Description: ZL-1102 3% w/w gel QD for 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ZL-1102 0% w/w gel BID for 16 weeks
Description: Vehicle 0% w/w gel BID for 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ZL-1102 0% w/w gel QD for 16 weeks
Description: Vehicle 0% w/w gel QD for 16 weeks
Study: NCT05596591

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused extracorporeal shockwave therapy
Description: High energy level shockwaves (between 0.28-0.60 mJ/mm\^2) will be focused over the subchondral bone with the bone marrow lesion, previously localized on MRI.
Study: NCT06284278

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing retraining
Description: 8 weeks diaphragmatic breathing training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic stabilization exercise
Description: 8 weeks pelvic stabilization exercise training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pelvic anatomy education
Description: pelvic anatomy education
Study: NCT06021990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel Bisulfate 75Mg Tab
Description: Severe COPD patients who meet eligibility criteria will be given Clopidogrel Bisulfate 75 mg Tablet daily, along with standard of care treatment till the completion of the study duration or any side effects that warrants stoppage of the drug
Study: NCT05571800

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mango
Description: 120g of fresh Mango

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200g isocaloric Granola Bar
Study: NCT06502015

Intervention type: DIAGNOSTIC_TEST
Intervention: biomaker levels
Description: this study will discover and validate novel biomarkers (including blood, feces, bone marrow and lymph nodes etc al) of various neurological autoimmune diseases

Intervention type: DIAGNOSTIC_TEST
Intervention: biomaker levels
Description: this study will discover and validate novel biomarkers (including blood, feces, bone marrow and lymph nodes etc al) of various neurological autoimmune diseases
Study: NCT06192706

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foldax Tria Aortic Valve
Description: Aortic Valve Replacement
Study: NCT04947969

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser acupuncture
Description: This study will use German-made low-level laser pen (Al-Ga-As diode laser, 810nm, NIR, Physiolaser Olympic Basic, RJ laser). The parameters are power of 100mW, frequency of Bahr, apply on acupoint. Well will irradiate each point for 2 J. Each patient will receive this treatment six times for one week.
Study: NCT06284278

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pelvic anatomy education
Description: pelvic anatomy education
Study: NCT04947969

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: laser acupuncture
Description: This study will use German-made low-level laser pen (Al-Ga-As diode laser, 810nm, NIR, Physiolaser Olympic Basic, RJ laser). The parameters are power of 100mW, frequency of Bahr, apply on acupoint. Well will irradiate each point for 2 J. Each patient will receive this treatment six times for one week.
Study: NCT05230082

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture treatments will be separated by a minimum of two days and a maximum of 14 days. Treatment sessions will be identical for both groups. Standard, sterile stainless-steel, disposable needles will be inserted at acupuncture points with a total of 18 needles for each treatment session. The depth of the needle will be approximately 10-20 millimeters. Needles will be left in place for 30 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture treatments will be separated by a minimum of two days and a maximum of 14 days. Treatment sessions will be identical for both groups. Standard, sterile stainless-steel, disposable needles will be inserted at acupuncture points with a total of 18 needles for each treatment session. The depth of the needle will be approximately 10-20 millimeters. Needles will be left in place for 30 minutes.
Study: NCT06049693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous Gluconate 300 MG
Description: Ferrous Gluconate 300 MG twice a day
Study: NCT06361797

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rotator cuff repair augmented with whole bone marrow
Description: Bone marrow derived from the proximal humerus will be aspirated during the rotator cuff repair. At the end of the procedure, the aspirate will be injected back into the joint space.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rotator cuff repair augmented with whole bone marrow
Description: Bone marrow derived from the proximal humerus will be aspirated during the rotator cuff repair. At the end of the procedure, the aspirate will be injected back into the joint space.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rotator cuff repair augmented with concentrated bone marrow
Description: Bone marrow derived from the proximal humerus will be aspirated during the rotator cuff repair. This volume will be concentrated and, at the end of the procedure, the concentrate will be injected back into the joint space.
Study: NCT06067893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patient receives dexmedetomidine for 48 hours post-operatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Patient receives normal saline for 48 hours post-operatively
Study: NCT05463471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound sodium acetate ringer injection
Description: Quickly infuse 500ml of compound sodium acetate ringer injection for volume expansion within 20-30 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin
Description: Quickly infuse 500ml of albumin for volume expansion within 20-30 minutes
Study: NCT05961631

Intervention type: OTHER
Intervention: Bio-electrical Impedance Analysis
Description: Variable measured: Fluid accumulation (FA), volume excess (VE), total body weight (TBW), extracellular water (ECW), intracellular water (ICW)

Intervention type: OTHER
Intervention: Bio-electrical Impedance Analysis
Description: Variable measured: Fluid accumulation (FA), volume excess (VE), total body weight (TBW), extracellular water (ECW), intracellular water (ICW)
Study: NCT05679934

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: Stretching and strengthening exercises will be applied to the participants

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: Stretching and strengthening exercises will be applied to the participants
Study: NCT06313346

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Probiotic capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules